@article{e6b8855e5e434b179b81f5c0df87b2d7,
title = "Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection",
abstract = "Background. Head and neck squamous cell carcinoma (HNSCC) cell lines are important preclinical models in the search for novel and targeted therapies to treat head and neck cancer. Unlike many other cancer types, a wide variety of primary and metastatic HNSCC cell lines are available. An easily accessible guide that organizes important characteristics of HNSCC cell lines would be valuable for the selection of appropriate HNSCC cell lines for in vitro or in vivo studies. Methods. A literature search was performed. Results. Cell growth and culture parameters from HNSCC cell lines were catalogued into tables or lists of selected characteristics. Methods for establishing cancer cell lines and basic cell culture maintenance techniques were reviewed. Conclusions. A compendium of HNSCC cell line characteristics is useful for organizing the accumulating information regarding cell line characteristics to assist investigators with the development of appropriate preclinical models.",
keywords = "Cell line, Characteristics, HNSCC, Head and neck cancer, SCCHN",
author = "Lin, {Charles J.} and Grandis, {Jennifer R.} and Carey, {Thomas E.} and Gollin, {Susanne M.} and Whiteside, {Theresa L.} and Koch, {Wayne M.} and Ferris, {Robert L.} and Lai, {Stephen Y.}",
note = "Funding Information: B.J.S.-J., M.H., and A.R.R. declare no competing interests. L.A.G. has served as a consultant for Pfizer and serves on the DSMB for Avrobio. M.V.R. has received research funding from Alnylam, Biomarin, Bioverativ, Sangamo, Spark, and Shire/Takeda and has participated in advisory boards for Alnylam, Biomarin, Bioverativ, and Spark. J.E.J.R. has received honoraria or speakers{\textquoteright} fees from GlaxoSmithKline, Miltenyi, Takeda, Gilead, Pfizer, Spark, Novartis, Celgene, and Bluebird Bio; has equity ownership in Genea and RareCyte; and is a consultant for RareCyte and Imago. L.J.R. has participated in advisory boards for Roche/Genentech, Bayer, CSL Behring, and Hema-Biologics. J.A.W., K.W., X.M.A., Y.C., K.K., F.M., and K.A.H. are employees or former employees of Spark Therapeutics. Funding Information: This work was additionally supported by National Institutes of Health grants K08 HL 146991-01 (to L.A.G.) and P01 HL64190 (to K.A.H., program director). We gratefully acknowledge the bravery of the study subjects whose contributions greatly contributed to current clinical development efforts of AAV-based therapeutics.",
year = "2007",
month = feb,
doi = "10.1002/hed.20478",
language = "English (US)",
volume = "29",
pages = "163--188",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "2",
}